New injectable treatment may help people quit fentanyl more effectively
NCT ID NCT06726200
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests whether a long-acting injectable form of buprenorphine works better than the standard sublingual (under-the-tongue) version for treating opioid use disorder in people who use fentanyl or other strong synthetic opioids. About 60 adults aged 18–65 will be enrolled and followed for 4 weeks after starting treatment. The goal is to see which formulation leads to more drug-free days and fewer relapses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Substance Treatment and Research Service
RECRUITINGNew York, New York, 10019, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.